This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab

This observational study is tracking how patients in China with severe eosinophilic asthma (a type of difficult-to-control asthma driven by high levels of certain immune cells) respond to a biologic treatment called benralizumab in real-world clinical settings. **You may be eligible if...** - You are 12 or older - You have been diagnosed with severe eosinophilic asthma and your doctor has prescribed benralizumab - Your blood eosinophil count meets the study thresholds (≥150/µL in the last 3 months or ≥300/µL in the past year) **You may NOT be eligible if...** - You are currently enrolled in another clinical trial - You do not have severe eosinophilic asthma - You are not being prescribed benralizumab by your doctor Talk to your doctor to see if this trial is right for you.